A Study of Lemborexant in Chinese Participants With Insomnia Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

March 17, 2023

Study Completion Date

March 17, 2023

Conditions
Sleep Initiation and Maintenance Disorders
Interventions
DRUG

Lemborexant

Lemborexant 10 mg tablet.

DRUG

Placebo

Placebo tablet matched to lemborexant 10 mg tablet.

Trial Locations (23)

Unknown

Beijing Tiantan Hosptial, Capital Medical University, Beijing

Peking University Sixth Hospital, Beijing

Xuanwu Hospital Capital Medical University, Beijing

Guangdong Provincial People's Hospital, Guangzhou

Nanfang Hospital of Southern Medical University, Guangzhou

The First Affiliated Hospital of Jinan University, Guangzhou

The First Hospital of Hebei Medical University, Shijiazhuang

The Third Hospital of Hebei Medical University, Shijiazhuang

Henan Mental Health Center, Xinxiang

Wuhan Mental Health Center, Wuhan

Nanjing Brain Hosptial, Nanjing

The Second Affiliated Hospital of Soochow University, Suzhou

The Second Affiliated Hospital of Nanchang University, Nanchang

Jilin First University Affiliated Hospital, Changchun

Inner Mongolia Autonomous Region Peoples Hospital, Hohhot

Tangdu Hospital, Xi'an

Shandong Provincial Qianfushan Hospital, Jinan

Huashan Hospital Fudan University, Shanghai

Shanghai Mental Health Center, Shanghai

First Hospital of Shanxi Medical University, Taiyuan

Tianjin Anding Hospital, Tianjin

Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital, Taoyuan

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT04549168 - A Study of Lemborexant in Chinese Participants With Insomnia Disorder | Biotech Hunter | Biotech Hunter